Mass. Movers

Insulet narrows loss in fourth quarter

An earlier version of Insulet’s OmniPod insulin pump.

An earlier version of Insulet’s OmniPod insulin pump.


Bedford’s Insulet Corp. said fourth-quarter 2013 revenue rose 19 percent to $68.5 million, compared to $57.8 million in the same period in 2012. Insulet said the revenue bump was a result of continued strong patient adoption of the OmniPod insulin pump in the United States and international markets. The company said its net loss was $2.5 million, or 4 cents per share, compared to a loss of $10.2 million, or 21 cents, in 2012. The results, however, beats analysts’ estimated loss of 9 cents.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of